Proteonomix, a developer of human cells based therapeutics, has licensed rights to use its anti-tumor technology. The technology comprises methods for isolation and propagation of the primary human cells, gene profiles obtained from the ...
Tags: Proteonomix, anti-tumor technology
Proteonomix, a biotechnology company, has announced Institutional Review Board (IRB) approval for its clinical trial of UMK-121 in patients with end stage liver disease. The company previously signed an agreement with the University of ...